Quasar Medical Expands Its Capabilities with Nitinol Design Center Acquisition
Quasar Medical Expands Its Capabilities with Nitinol Design Center Acquisition
Quasar Medical, a prominent global contract development and manufacturing organization (CDMO), has announced a significant acquisition that marks a strategic enhancement to its technology capabilities. On July 31, 2026, the company successfully acquired the Nitinol Design and Development Center previously owned by Medres International, based in San Diego, California. This acquisition effectively broadens Quasar's expertise in the design, development, and manufacturing of advanced Nitinol technologies, allowing the company to further solidify its position within the medical devices sector.
The San Diego facility spans 10,000 square feet and focuses on dedicated Nitinol operations, which are vital for the production of minimally invasive medical devices. With the integration of this state-of-the-art center, Quasar Medical is now equipped with specialized engineering talent and advanced manufacturing capabilities that will enhance the production quality of its offerings. This particular move is in alignment with the growing demand for sophisticated minimally invasive devices in the medical field, where Nitinol has become a critical enabling technology.
Nitinol, an alloy of nickel and titanium, is renowned for its unique properties, such as shape memory and superelasticity, making it essential for various medical applications. Quasar’s CEO, Alex Wallstein, stated that this acquisition represents a pivotal moment in the company's long-term growth strategy, enabling them to advance their production capabilities significantly. He emphasized that Nitinol's role in modern medical devices—ranging from minimally invasive disposables to implantable technologies—cannot be overstated.
Christine Trepanier, who serves as the Senior Vice President of Technology at Quasar, will oversee the integration of the San Diego Nitinol center with Quasar's existing facilities in Israel and Galway. Her leadership is expected to enhance the company's technical prowess further, allowing for innovative product development that adheres to the highest standards of quality and precision.
Furthermore, the acquisition introduces notable talents, such as Tom Duerig, recognized as a pioneer in bringing Nitinol into the realm of medical devices. His extensive experience as the founder of the Nitinol Device Corporation (NDC) adds invaluable insight to the Quasar team, facilitating the expansion of their Nitinol capabilities.
The San Diego facility is being positioned as Quasar Medical’s Nitinol design and development hub, anchoring efforts in comprehensive engineering support throughout the product lifecycle. Clients will benefit from the facility’s cutting-edge resources that facilitate early engineering collaboration and enhance overall product development efficiency. The Nitinol Design and Development Center will leverage Quasar’s global manufacturing network, thereby ensuring high-volume production is optimized for clients' needs.
Moreover, as Quasar Medical continues to emphasize innovation and complex engineering solutions, the San Diego center is set to provide:
- - Comprehensive Nitinol Expertise: Advanced capabilities in design, prototyping, and precision manufacturing processes.
- - Integrated Product Development: Collaborative efforts combining engineering with expertise in diverse medical device technology.
- - Accelerated Time to Market: Streamlined transitions from the initial concept to commercial production.
- - Global Scale and Quality: Access to ISO 13485-certified facilities, assuring quality excellence in operations.
Quasar Medical's acquisition not only enriches its technological repertoire but also signifies its commitment to enhancing patient outcomes through innovative medical solutions. This strategic investment in advanced technologies reflects the company's dedication to serving the evolving needs of medical device innovators who require high-performance products.
Dr. Chris Cheng, CEO and Chairman of Medres International, expressed excitement about the future of the Nitinol center, now under Quasar's management, highlighting increased resources and customer outreach that will guide the center toward achieving its full potential. This acquisition ultimately enables Medres to redouble its efforts on its core operations in Hungary, further strengthening both organizations' focus on growth.
For more information about Quasar Medical’s capabilities and the newly established Nitinol Design and Development Center, you can visit their website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.